dr. chowdhury on separate roles of pazopanib and pembrolizumab in rcc
Published 7 years ago • 183 plays • Length 0:58Download video MP4
Download video MP3
Similar videos
-
2:17
dr. chowdhury on pembrolizumab plus pazopanib in rcc
-
0:53
dr. chowdhury on sequencing of immunotherapy regimens for rcc
-
2:24
pazopanib and pembrolizumab: a dangerous combination for the treatment of rcc
-
2:58
real world effectiveness of pazopanib in patients with intermediate risk renal cell carcinoma
-
1:46
dr. bernard escudier on patients preferring pazopanib for metastatic renal cell carcinoma
-
6:30
pembrolizumab in combination with pazopanib
-
5:40
pazopanib and sunitinib in renal cell carcinoma
-
2:33
dr. hsieh discusses frontline treatment of kidney cancer with pazopanib and sunitinib
-
2:16
dr. amin on toxicities with immunotherapy/tki combinations in rcc
-
3:30
promising results for axitinib and pembrolizumab in advanced renal cell cancer
-
1:45
votrient (pazopanib)- advanced renal cell carcinoma (rcc), and advanced soft tissue sarcoma (sts)
-
0:54
dr. sankhala on the significance of trc105/pazopanib in angiosarcoma
-
7:14
dosing sunitinib and pazopanib in renal cell carcinoma
-
0:51
dr. schmidinger on managing side effects from targeted therapies in rcc
-
1:47
dr. schmidinger on side effects from targeted agents in renal cell cancer
-
8:27
checkpoint inhibition in renal cell carcinoma
-
2:32
dr. motzer on sunitinib versus pazopanib in renal cell carcinoma
-
0:54
dr. mcdermott on immunotherapy as a standard of care in rcc
-
2:16
the agents at the forefront of kidney cancer treatment